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Abstract
Background: The R47H variant of Triggering Receptor Expressed on Myeloid cells 2 (TREM2) confers greatly increased
risk for Alzheimer’s disease (AD), reflective of a central role for myeloid cells in neurodegeneration. Understanding how
this variant confers AD risk promises to provide important insights into how myeloid cells contribute to AD pathogenesis
and progression.
Methods: In order to investigate this mechanism, CRISPR/Cas9 was used to generate a mouse model of AD harboring
one copy of the single nucleotide polymorphism (SNP) encoding the R47H variant in murine Trem2. TREM2 expression,
myeloid cell responses to amyloid deposition, plaque burden, and neuritic dystrophy were assessed at 4 months of age.
Results: AD mice heterozygous for the Trem2 R47H allele exhibited reduced total Trem2 mRNA expression, reduced
TREM2 expression around plaques, and reduced association of myeloid cells with plaques. These results were comparable
to AD mice lacking one copy of Trem2. AD mice heterozygous for the Trem2 R47H allele also showed reduced myeloid
cell responses to amyloid deposition, including a reduction in proliferation and a reduction in CD45 expression around
plaques. Expression of the Trem2 R47H variant also reduced dense core plaque number but increased plaque-associated
neuritic dystrophy.
Conclusions: These data suggest that the AD-associated TREM2 R47H variant increases risk for AD by conferring a loss of
TREM2 function and enhancing neuritic dystrophy around plaques.
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Background
Alzheimer’s disease (AD) is accompanied by a robust
inflammatory response [1]. However, until recently, it
has been unclear whether myeloid cells (including
brain-resident microglia and possibly infiltrating mono-
cytes) actively contribute to AD pathogenesis and
progression. Recent Genome Wide Association Studies
have linked single nucleotide polymorphisms (SNPs) in
inflammation-related genes to increased AD risk [2],
including a SNP encoding the R47H variant in Trigger-
ing Receptor Expressed on Myeloid cells 2 (TREM2).
The TREM2 R47H variant not only constitutes one of
the strongest single allele genetic risk factors for AD [3,
4], but also confers elevated risk for Parkinson’s disease,
amyotrophic lateral sclerosis, and frontotemporal demen-
tia [5]. Furthermore, homozygous TREM2 variants cause
Nasu-Hakola disease, which is characterized by extensive
white matter loss and frontotemporal-like dementia [6].
These genetic studies definitively demonstrate that mye-
loid cell perturbations can contribute to neurodegenera-
tive disease. However, it remains unclear how the TREM2
* Correspondence: glandret@iu.edu
†Paul J. Cheng-Hathaway, Erin G. Reed-Geaghan and Taylor R. Jay
contributed equally to this work.
1Department of Neurosciences, Case Western Reserve University, School of
Medicine, Cleveland, OH 44106, USA
2Department of Anatomy and Cell Biology, Indiana University, School of
Medicine, Indianapolis, IN 46202, USA
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cheng-Hathaway et al. Molecular Neurodegeneration  (2018) 13:29 
https://doi.org/10.1186/s13024-018-0262-8
R47H variant alters myeloid cell function to enhance dis-
ease risk.
In the brain, TREM2 is expressed exclusively by mye-
loid cells [7, 8] and has been implicated in a diverse
range of myeloid cell functions [5]. A number of studies
have investigated the role of TREM2 in AD pathogenesis
using Trem2 deficient mice. Myeloid cells accumulate
around amyloid plaques in the AD brain, but the abun-
dance of these plaque-associated myeloid cells is sub-
stantially diminished in AD mice lacking Trem2,
consistent with its known roles in myeloid cell survival
and proliferation. Yuan et al. postulate that the loss of
plaque-associated myeloid cells promotes plaque expan-
sion and damage to surrounding neurites in Trem2 defi-
cient mice [9]. In support of this hypothesis, Trem2
deficient AD mice exhibit enhanced amyloid pathology
at late stages in disease [10, 11] accompanied by in-
creased plaque-associated neuritic dystrophy [9, 11, 12].
However, at early stages of disease progression, Trem2
deficiency reduces amyloid burden [10, 13].
While these studies have elucidated some important
aspects of TREM2 function in the context of AD, how
these studies relate to disease-associated TREM2 vari-
ants has only recently begun to be investigated. In vitro
studies have demonstrated that the TREM2 R47H vari-
ant reduces affinity for TREM2 ligand binding [9, 11,
14–18], and alters glycosylation [19, 20], leading to
speculation that the TREM2 R47H variant may result in
a loss of TREM2 function. The function of the R47H
variant was recently assessed for the first time in vivo.
Song et al. expressed the human TREM2 R47H variant
using a bacterial artificial chromosome (BAC) transgenic
and found that the R47H variant could not rescue as-
pects of TREM2 function in AD mice lacking endogen-
ous Trem2 expression [21]. This study is in agreement
with the in vitro data suggesting the TREM2 R47H vari-
ant results in a loss of TREM2 function. However, be-
cause of the approach used in this study, it is unclear
whether the loss of function phenotypes observed could
be attributed to impairments in association of human
TREM2 with mouse signaling pathways. In addition,
these mice expressed eight copies of the TREM2 gene
and, because TREM2 overexpression has previously been
associated with changes in microglial function and path-
ology [22], it is difficult to determine which phenotypes
observed in this study were due to the TREM2 R47H
variant or overexpression of the TREM2 protein. In the
current study, we use a complementary approach that
maintains endogenous regulation of Trem2 expression.
We address the critical question of how the R47H
Trem2 variant alters TREM2 function in vivo, including
AD-associated myeloid cell responses, using AD mouse
models in which CRISPR/Cas9 was used to knock the
R47H variant into the endogenous mouse Trem2 gene.
Using this model, we demonstrate that the Trem2 R47H
variant dramatically reduces TREM2 expression, com-
promising myeloid cell responses to AD-like amyloid
pathology. Furthermore, we are the first to demonstrate
that these myeloid cell changes with the R47H Trem2
variant alter plaque structure to enhance neuritic
dystrophy.
Methods
Contact for reagent and resource sharing
Further information and requests for resources and reagents
should be directed to corresponding authors Gary Landreth
(glandret@iu.edu) or Bruce Lamb (btlamb@iu.edu).
Experimental model
CRISPR/Cas9-mediated insertion of the SNP encoding the
TREM2 R47H variant into the mouse Trem2 gene was
performed by injecting embryos with Cas9, short-guide RNA
(sgRNA) and replacement oligo. The sequences are as
follows: Trem2 targeted region 3’-CGCAAGGCCTGGTG
TCGGCAGCTGGGTGAG, sgRNA (antisense) 5’-CCAC
AGCCGTCGACCCACTC, and replacement oligo 3’-CACA
AGGCTTGGTGTCGGCAGCTGGGTGAG. The first
codon in the replacement oligo corresponds to the SNP
encoding the R47H variant, while the third codon corre-
sponds to a silent mutation that ablates the protospacer ad-
jacent motif (PAM) site, necessary for initial binding of
CRISPR/Cas9. Using Sanger sequencing, mice from six dif-
ferent founder lines were identified to carry the SNP
encoding the TREM2 R47H mutation in either heterozygos-
ity or homozygosity. SNP-based genotyping (Thermo Fisher)
was used to identify carriers in subsequent crosses using the
following: forward primer: 5’-ATGTACTTATGACGCCTTG
AAGCA, reverse primer: 5’-ACCCAGCTGCCGACAC, SNP
reporter 1: 5’-CCTTGCGTCTCCC, SNP reporter 2:
5’-CCTTGTGTCTCCC.
In order to determine whether off-target mutations oc-
curred with CRISPR/Cas9-targeting, genomic DNA was
extracted using the DNeasy Blood and Tissue Kit (Qia-
gen, 69504) from F1 mice from four independently gen-
erated Trem2 R47H founder lines (R104, R202, R506,
and R1019) and independently maintained APPPS1–21;
Trem2+/+ or Trem2+/+ mice. HiSeqX Sequencing was
conducted with at least 30× coverage, 75% of bases
above Q30 at 2 × 150 bp (Garvan Institute of Medical
Research). Following alignment to the mouse reference
genome (MM9), the presence of insertion and deletion
mutations were assessed using the variant calling tools
GATK-HC and Samtools Mpileup. Sequences are avail-
able via http://www.ncbi.nlm.nih.gov under BioProject
accession PRJNA471261. CRISPR off-target prediction
software (http://www.crispor.tefor.net) was used to de-
termine potential off-target genes in exonic regions of
chromosome 17 [23]. Mutations are shown for the only
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predicted off-target gene Rab11fip3 and the CRISPR/
Cas-9 target (Additional file 1: Table S1). Additionally,
in order to address dysregulation of Trem-like genes
within 5 kb of the Trem2 locus that may affect myeloid
cell function [24], mutations were also assessed in
Treml1, Treml2, and Treml6. Mutations were detected
in lines R202 and R506 and these lines were therefore
not used for the current study. However, no off-target
mutations were identified in R104 or R1019 lines, consist-
ent with the low rate of expected off-target mutations due
to CRISPR/Cas9 targeting [25]. These two founder lines
were maintained independently and mice from genera-
tions F1-F3 were used in the analyses presented here.
Trem2 deficient mice (Trem2tm1(KOMP)Vlcg) with re-
placement of exons 2, 3, and part of 4 with LacZ were
used to generate Trem2+/+ and Trem2+/− controls. WT
Trem2 was genotyped using the following primers: forward
5’-TGGTGAGCACACACGGT, reverse 5’-TGCTCCCAT
TCCGCTTCTT and LacZ was genotyped using the follow-
ing primers: forward 5’-ATCACGACGCGCGCTGTATC,
reverse: 5’-ACATCGGGCAAATAATATC. Trem2R47H and
Trem2tm1(KOMP)Vlcg mice were crossed into the APPPS1–
21 AD mouse model (kindly provided by Mathias Jucker)
which expresses the Swedish APP mutation (KM670/
671NL) and the L166P mutation in PSEN1 driven under
the Thy-1 promoter [26]. All mice used in this study were
maintained on a C57BL6/J background. Both male and fe-
male mice were used in this study.
Method details
Tissue isolation
Following deep anesthetization with ketamine/xylazine, mice
were perfused with ice-cold PBS, and brains removed. For
immunohistochemistry, one hemisphere was drop-fixed in
4% PFA in PBS for 24–48 h, transferred and stored at 4 °C
in 30% sucrose in PBS. After embedding in OCT Com-
pound (VWR), 30 μm thick sections were obtained on a
Leica CM 1950 cryostat and stored in cryoprotection buffer
containing 30% sucrose, 1% PVP-40, and 30% ethylene gly-
col in 0.1 M phosphate buffer at − 20 °C until use.
For qPCR and ELISA studies, cortical and hippocam-
pal regions from the other hemisphere were microdis-
sected, snap frozen in liquid nitrogen, and stored at −
80 °C until proceeding to extraction. Tissue was homog-
enized in buffer containing 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, 1:100 protease inhibitor cocktail
(Sigma Aldrich, P8340). For Aβ extractions, brain ho-
mogenates were stored at − 80 °C. For qPCR, samples
were stored in an equal volume of RNA-Bee (Amsbio,
CS-104B) at − 80 °C until proceeding to RNA extraction.
Quantitative RT-PCR
RNA was isolated using phenol-chloroform extraction
and a Purelink RNA Mini Kit (Life Technologies) with
an on-column DNAse Purelink Kit (Life Technologies).
RNA-to-cDNA conversion was conducted on 500 ng
RNA with QuantiTech Reverse Transcription Kit
(Qiagen) and qPCR was conducted using a StepOne Real
Time PCR System with Taqman Assays (Life Technolo-
gies). Gene expression was normalized to Gapdh and
18s. Relative gene expression is graphed as fold change,
and ΔCT values were used for statistical analysis. The
following genes were assessed: Arg1 (Mm00475977_m1),
Fizz1 (Mm00445109_m1), Ym1 (Mm00657889_mH),
Il-1b (Mm00434228_m1), Il-6 (Mm00446191_m1), iNos
(Mm00440502_m1), Tlr4 (Mm445273_m1), Tnfa
(Mm443258_m1), and Trem2 (Mm04209424_g1).
Immunohistochemistry
Sections were permeabilized with PBS containing 0.1% Tri-
ton X-100. Antigen retrieval was conducted using 10 mM
sodium citrate, pH 6.0, with 0.5% Tween-20, except for
TREM2 and CD45 for which Reveal Decloaker (Biocare
Medical, RV1000) was used. Sections were exposed to anti-
gen retrieval for 10 min at 95 °C, cooled for 20 min, and
incubated in blocking buffer containing 5% normal goat
serum, 0.3% Triton X-100, in PBS. Sections were incubated
in primary antibodies diluted in blocking buffer overnight
at 4 °C, washed, and incubated in the appropriate
Alexa-Fluor-conjugated secondary antibodies at 1:1000 in
blocking buffer for 1 h at room temperature (RT). To
detect TREM2, sections were incubated in primary anti-
body for 48 h at 4 °C and secondary antibody for 6 h at RT.
Nuclei were counterstained with DAPI, and slices
were mounted and coverslipped with Prolong Gold
(Thermo Fisher, P36930). Mouse on Mouse Blocking Re-
agent (Vector Laboratories, MKB-2213) was used for pri-
mary antibodies generated in mouse or rat at 1:1000.
TREM2 (R&D Systems, AF1729), 6E10 (Bio Legend 9153–
005), IBA1 (Wako, 019–19741), Ki67 (Cell Signaling Tech-
nology, RM9106–50), CD45 (ABD Serotec, MCA1388),
and n-APP (EMD Milliopore, MAB348) were used at
1:500, and ubiquitin (Thermo Fisher PA1–10023) was used
at 1:2000. For dense core plaque staining, sections were
washed with PBS, mounted, and stained with 1% w/v Thio-
flavin S.
Aβ1–40 and Aβ1–42 ELISAs
Extraction of Aβ species was conducted as described
previously [27]. Briefly, cortical tissue-enriched homoge-
nates were combined in equal volume with 0.4% diethy-
lamine (DEA), subjected to ultracentrifugation, and
supernatant containing the soluble protein fraction was
neutralized with 0.5 M Tris-HCl. The pellet was dis-
solved in ice-cold 95% formic acid (FA), subjected to
ultracentrifugation, and supernatant containing the in-
soluble protein fraction was neutralized in buffer
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containing 0.5 M Tris base, 0.5 M Na2HPO4, and 0.05%
NaN3. Fractions were stored at − 80 °C until use.
For ELISA detection of Aβ1–40 and Aβ1–42, F8 Maxisorp
Nunc-Immuno Module (Thermo Fisher) wells were coated
with 6E10 ascites antibody (Bio Legend, SIG-39300) at
1:1000 diluted in 100 mM carbonate buffer, pH 9.6, over-
night at 4 °C. Wells were washed with PBS containing
0.025% Tween-20 and blocked with 1% nonfat milk in PBS
for 1 h at 37 °C. DEA fractions, FA fractions, and recombin-
ant Aβ1–40 (Bachem, 4014442) and Aβ1–42 (Bachem,
4061966) protein standards were diluted in PBS containing
0.025% Tween-20 and 0.5% BSA and incubated overnight at
4 °C. Following incubation with anti-Aβ1–40-conjugated
HRP (Biolegend, 805407) at 1:2500 or anti-Aβ1–42-conju-
gated HRP (Biolegend, 805507) at 1:1250 for 1 h at RT,
Aβ
1–40
and Aβ1–42 were detected using the Pierce TMB
Substrate Kit (Thermo Fisher, 34021) and a BioTek Syn-
ergy HTX plate reader at 450 nm. Total levels of Aβ were
normalized to total protein levels in each fraction using
the Pierce BCA Protein Assay Kit (Thermo Fisher, 23225)
and values are represented as fold change to APPPS1;
Trem2+/+ animals.
Image acquisition
Epifluorescent images for percent area and plaque bur-
den were acquired on a CTR5000 upright epifluorescent
microscope (Leica). Confocal images for IBA1-positive
cell number were obtained on a LSM 510 META micro-
scope (Zeiss).
Quantification and statistical analysis
Quantification of all immunohistochemistry experiments
was conducted by observers blinded to Trem2 genotype.
Values within one image were averaged together and
then averaged for each biological replicate. Data are
graphed as the mean ± SEM.
Plaque-associated percent area
Plaque-associated percent area of TREM2 and CD45
were assessed using one medial and one lateral matched
section per animal. Images were acquired from three
cortical regions (motor, somatosensory, and visual cor-
tex) and three hippocampal regions at 20× magnifica-
tion. A circular ROI centered on 6E10-positive plaques
was used to define regions for quantification. Images
were manually thresholded and quantified using the
Multi-measure ROI function in Image J (NIH).
Plaque-associated myeloid cell number
IBA1-positive cell number per plaque was assessed by
acquiring confocal Z stacks 0.25 um apart in one medial
and one lateral matched section per animal from three
cortical regions (motor, somatosensory, and visual cortex)
at 20× magnification. Stacks were collapsed into a single
image and the number of IBA1-positive cell soma within
the ROI centered around 6E10-positive plaques was
scored using Image J.
Proliferating myeloid cell number
The total number of Ki67, IBA1-double positive cells
within one medial and one lateral matched section per
animal was manually scored.
Plaque burden
For plaque burden, every 12th sagittal section (10–12
sections per animal) was stained with Thioflavin S or
6E10. Images were acquired from three cortical regions
(motor, somatosensory, and visual cortex) at 10× magni-
fication and the dorsal hippocampus at 5× magnification
per section. 6E10 and Thioflavin S-positive plaque num-
ber and area were quantified using the Particle Analysis
function in Image J following manual thresholding.
Dystrophic Neurite Area & Plaque Size
For the analyses relating plaque size to dystrophic neurite
area, images were acquired from three cortical regions
(motor, somatosensory, and visual cortex) and three hippo-
campal regions at 20× magnification from one medial and
one lateral matched section per animal. ROIs centered on
6E10-positive plaques were drawn individually for each
plaque to include the total area of plaque-associated dys-
trophic neurites (ubiquitin and n-APP). Following manual
thresholding, 6E10 immunoreactive plaque size and dys-
trophic neurite immunoreactive area for each respective
ROI was quantified using the Particle Analysis function in
Image J. Dystrophic neurite area was divided by 6E10
plaque size for each plaque. These values were averaged
within each image and then across images for each animal
to yield the results for dystrophic neurite area / plaque size.
Statistical analysis
Prism (Graphpad) was used for all statistical analyses.
Grubb’s test with a cutoff of α = 0.05 was used to deter-
mine statistical outliers. Statistical significance was de-
termined using a one-way or two-way ANOVA with
Bonferroni post hoc analysis, with p-values less than
0.05 considered as significant. Each n represents a single
biological replicate. Data shown are representative of
three independent experiments.
Supplemental material
Additional file 2: Figure S1 details the experimental
model, main findings in the manuscript across Trem2
R47H founder lines, Trem2 expression in non-AD trans-
gene expressing animals, and Trem2 expression by sex.
Additional file 3: Figure S2 details IBA1+ plaque number
according to plaque size and the expression of a panel of
inflammation-related genes. Additional file 4: Figure S3
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shows changes in expression of genes related to Aβ pro-
duction and Aβ species using ELISA. Additional file 1:
Table S1 provides the variant calls for mutations in the
off-target predicted gene Rab11fip3, Trem2, and Trem--
like genes in mice derived from the first cross from
Trem2 R47H founders.
Results
To assess whether the Trem2 R47H variant affects
TREM2 expression, myeloid cell function and pathology
in AD, we used CRISPR/Cas9 targeting to introduce the
G➔A single nucleotide polymorphism (SNP) encoding
the variant in the endogenous mouse Trem2 gene. Suc-
cessful knock in of Trem2 R47H was validated using
Sanger sequencing (Additional file 2: Figure S1A) and
whole genome sequencing did not identify any off-target
mutations (Additional file 1: Table S1). Founder lines posi-
tive for the SNP were crossed to the APPPS1–21 AD
mouse model [26], generating APPPS1–21;Trem2+/R47H
mice. Mice from two founder lines were maintained inde-
pendently and generations F1-F3 from both lines were
used throughout this study. While working with early
generations of these mice does increase the chance that
off-target mutations are present, we observed no sig-
nificant differences in phenotype between the two inde-
pendent lines (Additional file 2: Figure S1B). These
mice were compared to APPPS1–21;Trem2+/+ and
APPPS1–21;Trem2+/− at 4 months of age.
Trem2 R47H impairs the myeloid cell response to amyloid
pathology
To determine whether the Trem2 R47H variant affects
Trem2 expression, we evaluated Trem2 RNA levels in the
brains of Trem2+/+, and Trem2+/R47H mice and found a
significant 42% decrease in Trem2 RNA in Trem2+/R47H
mice compared to Trem2+/+ mice (Additional file 2: Figure
S1C). This suggests that the Trem2 R47H variant impairs
TREM2 expression when endogenous regulation of its
expression is maintained, an important consideration
when interpreting previous in vitro studies in which
Trem2 R47H expression is induced at WT levels. A sig-
nificant reduction was observed in Trem2 expression in
APPPS1–21;Trem2+/R47H mice compared to APPPS1–
21;Trem2+/+ mice (64% in the hippocampus), similar to
the levels observed in APPPS1–21;Trem2+/− mice (Fig. 1b,
Additional file 2: Figure S1D). This reduction in Trem2
expression in the context of AD suggests that, in addition
to reducing baseline Trem2 expression, the Trem2 R47H
variant may also impair upregulation of Trem2 expression
in response to AD pathology.
As TREM2 protein expression in the AD brain is primarily
upregulated on plaque-associated myeloid cells [9, 13], we
Fig. 1 TREM2 expression is significantly reduced in AD mice expressing the Trem2 R47H variant. a Immunohistochemistry was used to identify
myeloid cells (IBA1, green), plaques (6E10, blue), and TREM2 (red). b Trem2 RNA levels were assessed in cortical and hippocampal lysates from
APPPS1–21;Trem2+/+ (n = 14), APPPS1–21;Trem2+/− (n = 13), and APPPS1–21;Trem2+/R47H (n = 10) mice. Data are presented as fold change
normalized gene expression relative to Trem2+/+ mice (n = 9). c Images were quantified to assess TREM2-immunoreactive area and (d) the
ratio of TREM2 to IBA1 immunoreactive area around plaques (n = 10–13 mice / genotype). Data are presented as mean± SEM. *p<0.05; ***p<0.001;
ns - not significant. Representative images are from the cortex
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next evaluated how TREM2 expression was affected in this
cell population. Similar to the observed reductions in Trem2
RNA, the Trem2 R47H variant resulted in a significant re-
duction in plaque-associated TREM2 protein expression in
APPPS1–21; Trem2+/R47H mice compared to APPPS1–21;
Trem2+/+ mice (45% reduction in the cortex and 51% reduc-
tion in the hippocampus), similar to the levels observed in
APPPS1–21; Trem2+/− mice (Fig. 1a and c). This reduction
in plaque-associated TREM2 protein expression could be
due to a reduction in cellular TREM2 expression or due to a
reduction in the number of plaque-associated myeloid cells.
We found that altered TREM2 expression was not
solely due to changes in the presence of myeloid cells
around plaques, as TREM2 percent area was still signifi-
cantly reduced when normalized to the myeloid cell
marker IBA1 (Fig. 1d). Together, these data suggest that
the Trem2 R47H variant reduces TREM2 expression in
the context of AD.
It has been consistently reported that Trem2 deficiency
leads to a specific reduction in accumulation of myeloid
cells around plaques, while not significantly affecting
non-plaque-associated myeloid cell number [9–13, 28,
29]. To assess whether the Trem2 R47H variant confers
a similar phenotype, we examined the number of IBA1
positive cells around plaques. We found a significant
reduction in the number of plaque-associated myeloid
cells in APPPS1–21; Trem2+/R47H mice compared to
APPPS1–21; Trem2+/+ mice (37% reduction in the cor-
tex and 39% in the hippocampus), at levels comparable
to APPPS1–21; Trem2+/− mice (Fig. 2a), which was
consistent across plaque size (Additional file 3: Figure
S2A). Thus, AD mice expressing the Trem2 R47H variant
exhibit an impairment in myeloid cell accumulation
around plaques consistent with a loss of TREM2 function.
We previously reported that Trem2 deficiency results
in preferential loss of CD45hi-expressing myeloid cells
around plaques [10, 13]. Canonically, CD45hi has been
used to identify peripherally derived myeloid cells [30],
though we cannot exclude the possibility that these cells
represent a phenotypically distinct subset of reactive
microglia. Regardless of their provenance, TREM2 has
been shown to be required for accumulation of this cell
population in the AD brain. We found a significant
reduction in the area of high CD45 immunoreactivity
around plaques in APPPS1–21; Trem2+/R47H mice rela-
tive to APPPS1–21; Trem2+/+ mice (33% reduction in
cortex, 21% in hippocampus), comparable to the reduc-
tion observed in APPPS1–21; Trem2+/− mice (Fig. 2b).
Similar to what has been observed with Trem2 defi-
ciency, our findings suggest the Trem2 R47H variant
preferentially reduces accumulation of myeloid cells
expressing high levels of CD45 around plaques.
Fig. 2 Plaque-associated myeloid cells are reduced in mice expressing the Trem2 R47H variant. a Immunohistochemistry was used to quantify the
number of myeloid cells (IBA1, green) around plaques (6E10, blue). b Cells expressing high levels of CD45 (magenta) around plaques (6E10, blue)
were identified by immunohistochemistry and the percent CD45-positive area per plaque was quantified. c Proliferating (Ki67-positive, red)
myeloid cells (IBA1-positive, green) were quantified across the entire cortex and hippocampus from one medial and one lateral section. Data
from APPPS1–21; Trem2+/+ (n= 8), APPPS1–21;Trem2+/− (n= 8), and APPPS1–21;Trem2+/R47H (n = 10) mice are represented as mean ± SEM. *p < 0.05; **
p < 0.01; ***p < 0.001; ns - not significant. Representative images are from the cortex
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The Trem2 R47H variant could also contribute to re-
duced myeloid cell number around plaques by increasing
myeloid cell death or decreasing myeloid cell prolifera-
tion [10, 12]. We only rarely observed cleaved caspase-3
positive myeloid cells across genotypes, so we were un-
able to assess how the Trem2 R47H variant affected
myeloid cell death. However, proliferation of myeloid
cells, assessed using immunohistochemistry to identify
Ki67+ IBA1+ cells, was reduced in APPPS1–21; Trem2+/
R47H mice compared to APPPS1–21; Trem2+/+ mice
(35% reduction in cortex, 27% in hippocampus), similar
to APPPS1–21; Trem2+/− mice (Fig. 2c). These findings
suggest the Trem2 R47H variant reduces plaque associ-
ated myeloid cells, at least in part, through reducing
myeloid cell proliferation.
Recent work suggests that TREM2 is required for the
myeloid cell-mediated inflammatory response in AD [28,
31]. Therefore, we wanted to assess whether the Trem2
R47H variant would also impair the inflammatory response
to AD pathology. Relative to controls, we detected a signifi-
cant increase in the RNA levels of Arg1, Ym1, and Fizz1,
similar to our previous observations in Trem2 deficient AD
mice (Additional file 3: Figure S2B) [13]. Interestingly, we
also observed a significant increase in IL-6 in mice with the
Trem2 R47H variant. None of these cortical gene expres-
sion changes were evident in APPPS1–21; Trem2+/− mice.
There were also significant increases in Fizz1 and IL-6 in
hippocampal lysates from APPPS1–21; Trem2+/R47H and
APPPS1–21; Trem2+/− mice relative to APPPS1–21;
Trem2+/+ controls (Additional file 3: Figure S2C). A more
detailed analysis will be required to fully address the role of
Trem2 R47H on inflammatory responses in AD.
Trem2 R47H reduces compact plaque number
Reduced accumulation of myeloid cells around plaques due
to loss of TREM2 has previously been shown to result in
changes in plaque deposition [10, 11, 13]. Trem2 deficiency
alters plaque burden in a disease progression-dependent
manner, increasing plaque accumulation at advanced
disease stages, but reducing plaque accumulation early in
disease [10]. Consistent with earlier plaque deposition in
the cortex relative to the hippocampus in APPPS1–21
mice, at 4 months of age, previous studies found a reduc-
tion in amyloid accumulation in the hippocampus with
Trem2 deficiency, but no significant differences in the cor-
tex [13]. These changes occurred independent of changes
in AD transgene expression, which we also found were un-
altered in mice expressing the Trem2 R47H variant [10]
(Additional file 4: Figure S3A). In order to assess whether
the Trem2 R47H variant modifies total plaque burden, we
measured the number and percent area of 6E10 positive
plaques. While a modest increase in total cortical plaque
number and percent area were noted in APPPS1–
21;Trem2+/− mice compared to APPPS1–21;Trem2+/+ mice,
no difference in 6E10 positive plaque number or percent
area was observed in APPPS1–21; Trem2+/R47H mice
(Fig. 3a). Previous studies have demonstrated that Trem2
deficient mice exhibit a shift in plaque structure, from com-
pact, fibrillar plaques to diffuse plaques [9]. To determine
whether the Trem2 R47H variant affected the relative abun-
dance of these different plaque types, we quantified the
number and percent area of fibrillar, thioflavin S positive
plaques. A significant reduction in thioflavin S positive
plaque number (31%) and percent area (36%) were ob-
served in the hippocampus of APPPS1–21; Trem2+/R47H
mice compared to APPPS1–21; Trem2+/+ mice (Fig. 3b).
To assess whether this shift in plaque morphology was
due to alterations in the presence of different Aβ species,
we used ELISAs to assess soluble and insoluble Aβ1–40
and Aβ1–42. We observed a significant decrease in soluble
Aβ1–40 in the cortex of APPPS1–21; Trem2
+/R47H mice
compared to APPPS1–21;Trem2+/+ mice (Additional file 4:
Figure S3B), and thus an increased ratio of Aβ42/40
(Additional file 4: Figure S3C) in APPPS1–21; Trem2+/
R47H mice relative to APPPS1–21; Trem2+/+ controls. We
also observed a significant increase in soluble Aβ1–40 in
the hippocampus of APPPS1–21; Trem2+/− mice com-
pared to APPPS1–21; Trem2+/+ mice but no significant
changes in other Aβ species in mice expressing the Trem2
R47H variant. Together, these data suggest that changes in
the relative abundance of these species are not the pri-
mary contributor to changes in plaque structure in mice
with the Trem2 R47H variant. However, fibrillar plaques
are specifically reduced in mice bearing the Trem2 R47H
variant, consistent with results from Trem2 deficient mice
and human carriers of TREM2 R47H [9].
Trem2 R47H significantly increases plaque-associated
neuritic dystrophy
Damage to axons and dendrites in the vicinity of plaques,
termed neuritic dystrophy, is thought to contribute to cog-
nitive impairment in AD [32] and is reported to be
enhanced in AD mice lacking Trem2 and humans carrying
an R47H allele [9, 12]. To determine whether the changes
in plaque structure observed in AD mice with the Trem2
R47H variant similarly affected neuritic dystrophy, we next
analyzed plaque-associated N-terminal APP (n-APP), which
is elevated in dystrophic neurites due to impaired antero-
grade transport, and ubiquitin, which is increased in re-
sponse to cellular stress and protein dyshomeostasis. A
significant 33% increase in ubiquitin percent area around
plaques was observed in the hippocampus of APPPS1–
21;Trem2+/R47H mice compared to APPPS1–21;Trem2+/+
mice, similar to levels in APPPS1–21;Trem2+/− mice
(Fig. 4a). Comparable trends in neuritic dystrophy were ob-
served using the additional dystrophic neurite marker
n-APP, though the changes with Trem2 genotype were only
significant in the cortex of APPPS1–21;Trem2+/− mice
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relative to APPPS1–21;Trem2+/+ mice (Fig. 4b). The ratio
of ubiquitin area to plaque size was significantly increased
in APPPS1–21;Trem2+/R47H mice compared to APPPS1–
21;Trem2+/+ mice (Fig. 4c). Interestingly, the correlation be-
tween plaque size and ubiquitin positive area was preserved
across genotypes (Fig. 4d and e) and there was a trend to-
ward an increase in the slope of the best fit line between
ubiquitin positive area and plaque size in mice with the
Trem2 R47H variant (Fig. 4f). This indicates that larger pla-
ques may be even more strongly affected by the loss of
TREM2 function. Together, our data demonstrate overall
enhanced neuritic dystrophy with the Trem2 R47H variant,
when normalized to plaque size, suggesting a possible mech-
anism by which the variant could increase synaptic loss and
neuronal dysfunction, and ultimately confer AD risk.
Discussion
In order to investigate how the Trem2 R47H variant affects
TREM2 function and AD pathology, we developed a
CRISPR/Cas9 knock-in of the R47H variant into the mouse
Trem2 gene. Because this approach maintains endogenous
regulation of TREM2 expression, we were able to deter-
mine that expression of one copy of the R47H variant re-
duces Trem2 expression in a wild-type background and
further impairs upregulation of Trem2 expression in an AD
mouse model. This finding differs from a previous study
that found no changes in TREM2 expression in postmor-
tem tissue from human AD patients heterozygous for the
TREM2 R47H variant [33]. While many factors could con-
tribute to this discrepancy, Trem2 levels are known to
change throughout disease progression [13], and our study
evaluates Trem2 changes at a relatively early stage in path-
ology in the APPPS1–21 model, while the postmortem
samples are from humans at a late stage in disease. It will
be interesting to assess in future studies whether Trem2
levels are differentially affected by the R47H variant
throughout disease progression.
Importantly, this finding also merits consideration
when interpreting studies of TREM2 R47H function in
vitro, which have all used systems where Trem2 R47H
Fig. 3 Compact plaque number is specifically reduced in mice expressing the Trem2 R47H variant. Quantification of plaque burden was
performed in APPPS1–21;Trem2+/+ (n = 15), APPPS1–21;Trem2+/− (n = 13), and APPPS1–21;Trem2+/R47H (n = 10) mice by (a) measuring 6E10 (red)
and (b) Thioflavin S (green) positive plaque number and percent area across three cortical and one hippocampal region from 10 to 12 sagittal
sections. Higher magnification of cortical (i) and hippocampal (ii) regions are shown. Data are presented as mean ± SEM. *p < 0.05; **p < 0.01
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expression is maintained at WT levels, and the recent
evaluation of Trem2 R47H variant function using BAC
transgenics where Trem2 was overexpressed. It is pos-
sible that the observed loss-of-function phenotypes may
arise, at least in part, through reduced expression of
TREM2. Furthermore, by knocking the R47H variant
into the mouse Trem2 gene, we maintain the appropriate
interaction of mouse TREM2 with its endogenous
ligands and signaling molecules. However, despite a high
degree of homology between human TREM2 and mouse
Trem2 genes, it is possible that the R47H variant affects
human TREM2 differently than it affects mouse TREM2
structure and function. This caveat of our approach is ad-
dressed by complementary work using a BAC to express
human TREM2 R47H in Trem2-deficient AD model [21].
Notably, our CRISPR/Cas9 knock-in approach and their
BAC transgenic yield comparable results in myeloid cell
accumulation around plaques, Together, these findings
suggest that the Trem2 R47H variant confers phenotypes
consistent with loss of TREM2 function in a mouse model
of AD-like amyloid deposition.
AD mice expressing the Trem2 R47H variant exhibit re-
duced plaque-associated myeloid cells. We find that this
is, in part, due to reduced proliferation. In addition, we
demonstrate a selective reduction in plaque-associated
cells expressing high levels of CD45 in mice expressing
the Trem2 R47H variant. It remains unclear whether the
reduction in myeloid cell number represents impaired re-
cruitment or survival of peripherally derived macrophages
in the AD brain or diminished phenotypic conversion of
resident microglia to adopt expression of this marker.
Other possible mechanisms may also contribute to the
reduction of myeloid cells around plaques in mice ex-
pressing the Trem2 R47H variant, including deficits in
myeloid cell migration [34] and survival [11].
The alterations in myeloid cell accumulation are also
reflected by changes in inflammation-related gene expres-
sion. While changes in hippocampal gene expression are
largely similar between APPPS1–21;Trem2+/R47H mice
and APPPS1–21;Trem2+/− mice, in the cortex, increases
in mRNA levels of Arg1, Fizz1, Ym1 and IL-6 are specific
to mice expressing the Trem2 R47H variant. This demon-
strates that there are some functional measures in which
the R47H variant does not completely phenocopy loss of
one copy of Trem2. These differences in cortical gene ex-
pression between APPPS1–21;Trem2+/R47H and APPPS1–
21;Trem2+/− mice are not reflected in differences in the
other myeloid cell phenotypes or features of pathology
assessed in this manuscript. Additional experiments will
be required to fully address whether these region-specific
alterations in gene expression relate to other meaningful
differences in myeloid cell function and pathology.
Our data show that the Trem2 R47H variant does not
alter 6E10 positive plaque burden, but does reduce com-
pact, thioflavin S positive plaques, suggesting that the
changes in myeloid cell function mediated by the Trem2
R47H variant result in altered plaque structure. Yuan et al.
suggested that this could be due to impaired accumulation
of myeloid cells around plaques, which may normally limit
plaque growth. However, it has also been shown that
TREM2 influences the phagocytic activity of myeloid cells,
which could also contribute to changes in plaque structure.
It has been previously postulated that myeloid cells form
a barrier around plaques, protecting surrounding neurites
Fig. 4 Neuritic dystrophy is increased in APPPS1–21 mice expressing the Trem2 R47H variant. a Immunohistochemistry was used to quantify
dystrophic neurites in APPPS1–21;Trem2+/+ (n = 16), APPPS1–21;Trem2+/− (n = 15), and APPPS1–21;Trem2+/R47H (n = 10) mice by measuring (a)
ubiquitin (magenta) and (b) N-terminal APP (n-APP, red) % area across the cortex and hippocampus. c Dystrophic neurite area (ubiquitin, magenta)
normalized to plaque (6E10, blue) size was assessed in APPPS1–21;Trem2+/+ (n = 16), APPPS1–21;Trem2+/− (n = 15), and APPPS1–21;Trem2+/R47H (n = 10)
mice. d The correlation between ubiquitin positive area and plaque size was plotted for one representative animal per Trem2 genotype and (e) r2 and
(f) slope for the linear best fit lines were calculated. Data are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001
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from damaging Aβ species [35], leading to the prediction
that impaired association of myeloid cells with plaques
would increase neuritic dystrophy. Indeed, studies have pre-
viously shown enhanced neuritic dystrophy with reduced
myeloid cell plaque coverage in AD mice deficient for
Trem2, and in AD patients carrying the TREM2 R47H vari-
ant [9, 12]. Consistent with these findings, we observed an
increase in dystrophic neurites, relative to plaque size, in
mice expressing the Trem2 R47H variant. However, it has
also been shown that larger plaques typically have less
microglial coverage and more neuritic dystrophy. Thus, we
expected that reduced myeloid cell accumulation around
plaques with changes in Trem2 genotype would preferen-
tially increase neuritic dystrophy around small plaques, and
have less impact on larger plaques, since these plaques
already exhibit little myeloid cell coverage. In contrast,
however, we find that dystrophic neurite area correlated just
as strongly with plaque size in both APPPS1–21;Trem2+/
R47H and APPPS1–21;Trem2+/− mice. Furthermore, there
was a trend toward an increase in the slope between
dystrophic neurite area and plaque size in APPPS1–
21;Trem2+/R47H and APPPS1–21;Trem2+/− mice relative to
controls, suggesting that larger plaques may be even more
strongly affected by the loss of TREM2 function, and con-
sequently reduced accumulation of plaque-associated mye-
loid cells. Together, these data are suggestive of additional
roles for TREM2 in modulating neuritic dystrophy other
than limiting access of plaque species to surrounding neur-
ites. These findings suggest that TREM2 may be involved
in other mechanisms of dystrophic neurite formation, or
perhaps more likely, given its demonstrated role of phago-
cytosis in vitro, in the clearance of these dystrophic neurites
[5]. It will be important to determine whether the enhanced
neuritic dystrophy also correlates with neurodegeneration
and cognitive deficits.
A central question arising from this work is how the
changes observed in our study relate to the approximate
three-fold elevation in AD risk in heterozygous carriers of
the TREM2 R47H variant. Our data demonstrate that the
Trem2 R47H variant impairs TREM2 function, in part by
reducing TREM2 expression. This results in a reduced
myeloid cell response to AD pathology, and increased
neuritic dystrophy. Our results highlight the important
functional roles of myeloid cells in AD pathogenesis and
progression, and suggest that enhancing TREM2 signaling
may be beneficial in the context of sporadic AD. In
addition, because the TREM2 R47H variant confers risk
for other neurodegenerative diseases, this study also pro-
vides a basis for understanding important myeloid cells
functions and provides potential avenues for therapeutic
targets in other disease contexts. Collectively, under-
standing the mechanism by which the Trem2 R47H
variant affects myeloid cell function and pathology
across multiple disease models promises to decipher
common mechanisms by which myeloid cells modu-
late neurodegenerative disease pathology.
Conclusions
In summary, our findings indicate that the Alzheimer’s
disease-associated Trem2 R47H variant confers a loss of
TREM2 function, impairing myeloid cell responses to
pathology. This results in a reduction in TREM2 expres-
sion, myeloid cell proliferation, reduced compact plaque
burden and enhanced neuritic dystrophy in an Alzheimer’s
disease mouse model. These findings were comparable to
AD mice lacking one copy of Trem2.
Additional files
Additional file 1: Table S1. Variant calling for APPPS1–21;Trem2+/R47H
mice for the CRISPR predicted off target gene Rab11fip3, Trem2, and
Trem-like genes Treml1, Treml2, and Treml6. “0/1” indicates a heterozygous
variant and “./.” indicates no variants detected. Variants detected in Trem2
R47H lines but not APPPS1–21; Trem2+/+ or Trem2+/+ mice were considered
to be true. (XLSX 14 kb)
Additional file 2: Figure S1. (A) The SNP encoding for the arginine-to-
histidine missense mutation was knocked into exon 2 of mouse Trem2 using
CRISPR/Cas9 targeting. The sequences for the reference genome, guide RNA
(antisense), and homology directed repair (HDR) oligonucleotide containing
the AD-associated R47H variant (red) and a silent mutation (blue) to ablate the
protospacer adjacent motif (PAM), are indicated. Sanger sequence alignment
from a representative Trem2+/R47H mouse is shown. (B) Comparison of major
findings across two independently generated Trem2 R47H founder lines are
shown for APPPS1–21; Trem2+/R47H mice from line R104 (n= 7) and line R1019
(n= 3). (C) RNA levels of Trem2 were assessed in cortical lysates from Trem2+/+
(n= 9), and Trem2+/R47H (n= 10) mice. (D) RNA levels of Trem2 were assessed
in cortical and hippocampal lysates from APPPS1–21;Trem2+/+ (n= 6 females,
n= 6 males), APPPS1–21;Trem2+/− (n= 5 females, n= 8 males), and APPPS1–
21;Trem2+/R47H (n= 5 females, n= 5 males) mice. Data are presented as fold
change normalized gene expression relative to Trem2+/+ mice (n= 4 females,
n= 4 males) and were analyzed using a two-way ANOVA. *p< 0.05; ***p<
0.001; ns - not significant. (TIF 9131 kb)
Additional file 3: Figure S2. (A) IBA1+ cell number per plaque was
assessed relative to plaque size in cortex from APPPS1–21;Trem2+/+
(n = 4), APPPS1–21;Trem2+/− (n = 6), and APPPS1–21;Trem2+/R47H (n = 4) mice.
Data are presented as mean ± SEM. (B) Inflammation-related genes were
assessed in cortical and (C) hippocampal lysates from APPPS1–21;Trem2+/+
(n = 15), APPPS1–21;Trem2+/− (n = 12), and APPPS1–21;Trem2+/R47H (n = 10)
mice. Data are presented as fold change normalized gene expression,*p <
0.05, **p < 0.01, ****p < 0.0001. (TIF 9131 kb)
Additional file 4: Figure S3. (A) Expression of amyloid precursor protein
(App) and related genes were assessed in cortical lysates from APPPS1–
21;Trem2+/+ (n= 13), APPPS1–21;Trem2+/− (n= 13), and APPPS1–21;Trem2+/R47H
(n= 8) mice. Data are presented as fold change normalized gene expression.
(B) ELISAs for Aβ1–40 and Aβ1–42 and (C) ratio of Aβ1–42/Aβ1–40 were performed
on DEA (soluble) and FA (insoluble) fractions from cortex and hippocampus
from APPPS1–21;Trem2+/+ (n= 17), APPPS1–21;Trem2+/− (n= 14), and APPPS1–
21;Trem2+/R47H (n= 10) mice. Data are presented as fold change normalized
protein expression. *p< 0.05, **p< 0.01. (TIF 9131 kb)
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